RCT | Adjuvant nivolumab plus ipilimumab not better than placebo for localized renal cell carcinoma after nephrectomy
16 Feb, 2023 | 15:15h | UTCAdjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)